Takeda assesses financial impact from Novartis’ withdrawal of marketing authorisation application for Xiidra
OSAKA: Takeda Pharmaceutical Company Limited announced the anticipated financial impact from Novartis Europharm Limited’s withdrawal of the Marketing Authorisation Application (MAA) for Xiidra in Europe,...